SAN DIEGO, Sept. 2, 2020 /PRNewswire/ -- Viking
Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders,
today announced that the company will participate in four
upcoming investor conferences.
Details of the company's participation are as follows:
- Citi's 15th Annual BioPharma
Conference
Details: Viking management will
participate in 1-on-1 meetings
Conference Date: September 9-10,
2020
Format: Virtual Conference
- Morgan Stanley Global Healthcare Conference
Details:
Viking management will participate in 1-on-1 meetings
Conference Date: September 14-16,
2020
Format: Virtual Conference
- Cantor Fitzgerald Virtual Global Healthcare
Conference
Details: Viking management will deliver a
corporate presentation (webcast available) and participate in
1-on-1 meetings
Conference Date: September 15-17,
2020
Presentation Time/Date: 12:00 p.m.
Eastern on Thursday, September 17,
2020
Format: Virtual Conference
- Oppenheimer Fall Healthcare Life Sciences & MedTech
Summit
Details: Viking management will deliver a corporate
presentation (webcast available) and participate in 1-on-1
meetings
Conference Date: September 21-23,
2020
Format: Virtual Conference
The Cantor Fitzgerald and Oppenheimer presentations will be
webcast live and may be accessed via a link on the Viking
Therapeutics website in the Investors & Media section under
Webcasts. Additionally, replays of the webcasts will be
available on the Viking website following the
conferences.
About Viking Therapeutics, Inc.
Viking Therapeutics is a clinical-stage biopharmaceutical
company focused on the development of novel, orally available,
first-in-class or best-in-class therapies for the treatment of
metabolic and endocrine disorders. Viking's research and
development activities leverage its expertise in metabolism to
develop innovative therapeutics designed to improve patients'
lives. The company's clinical programs include VK2809, a
novel, orally available, small molecule selective thyroid hormone
receptor beta agonist for the treatment of lipid and metabolic
disorders, which is currently being evaluated in a
Phase 2b study for the treatment of biopsy-confirmed
non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase
2 trial for the treatment of non-alcoholic fatty liver disease
(NAFLD) and elevated LDL-C, patients who received VK2809
demonstrated statistically significant reductions in LDL-C and
liver fat content compared with patients who received
placebo. The company is also developing VK0214, a novel,
orally available, small molecule selective thyroid hormone receptor
beta agonist for the treatment of X-linked adrenoleukodystrophy
(X-ALD). The company holds exclusive worldwide rights to a
portfolio of five therapeutic programs, including those noted
above, which are based on small molecules licensed from Ligand
Pharmaceuticals Incorporated.
For more information about Viking Therapeutics, please visit
www.vikingtherapeutics.com. Follow Viking on Twitter
@Viking_VKTX.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-in-upcoming-investor-conferences-301123211.html
SOURCE Viking Therapeutics, Inc.